Review
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design
Affiliations
- PMID: 9594927
Item in Clipboard
Review
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design
Can J Cardiol.
1998 Apr.
Abstract
Evidence supports the idea that substantial benefits may derive from treatments that increase high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein (apo) A-I, HDL2 (or 2b) or the size of HDL particles with, or without, apo A-II. HDL3 appears to be neutral in terms of coronary artery disease risk, and apo A-II appears to be adverse. Because HDL particles serve as antioxidants in vitro, the hypothesis that low HDL-C reflects an antioxidant deficiency state appears tenable. Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997.
Similar articles
-
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).Am J Cardiol. 2004 Feb 1;93(3):307-12. doi: 10.1016/j.amjcard.2003.10.009. Am J Cardiol. 2004. PMID: 14759379 Clinical Trial.
-
Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.Indian Heart J. 2008 May-Jun;60(3):215-22. Indian Heart J. 2008. PMID: 19240310
-
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498. J Indian Med Assoc. 2006. PMID: 17388006 Clinical Trial.
-
Niacin-based therapy for dyslipidemia: past evidence and future advances.Am J Manag Care. 2002 Sep;8(12 Suppl):S315-22. Am J Manag Care. 2002. PMID: 12240703 Review.
-
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.Curr Med Res Opin. 2004 Aug;20(8):1253-68. doi: 10.1185/030079904125004402. Curr Med Res Opin. 2004. PMID: 15324528 Review.
Cited by
-
New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.Curr Atheroscler Rep. 2001 Sep;3(5):365-72. doi: 10.1007/s11883-001-0074-z. Curr Atheroscler Rep. 2001. PMID: 11487447 Review.
-
Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS).J Clin Lipidol. 2007 Jul;1(3):203-210. doi: 10.1016/j.jacl.2007.05.003. J Clin Lipidol. 2007. PMID: 18591993 Free PMC article.
-
Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.Cochrane Database Syst Rev. 2017 Jul 30;7(7):CD000253. doi: 10.1002/14651858.CD000253.pub4. Cochrane Database Syst Rev. 2017. PMID: 28756617 Free PMC article.